Compare BUDA & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUDA | EQ |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.1M | 89.4M |
| IPO Year | 2025 | 2018 |
| Metric | BUDA | EQ |
|---|---|---|
| Price | $5.30 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $13.00 | $8.56 |
| AVG Volume (30 Days) | 6.8K | ★ 299.9K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $12,609,000.00 | ★ $41,095,000.00 |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $21.29 | N/A |
| P/E Ratio | $37.93 | ★ N/A |
| Revenue Growth | ★ 11.84 | N/A |
| 52 Week Low | $5.26 | $1.04 |
| 52 Week High | $12.00 | $6.20 |
| Indicator | BUDA | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 33.53 |
| Support Level | N/A | N/A |
| Resistance Level | $7.86 | $1.54 |
| Average True Range (ATR) | 0.58 | 0.13 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 3.33 | 6.09 |
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.